ClinicalTrials.gg
RecruitingNCT07038382Updated Nov 18, 2025

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

A Phase 2 interventional study of HLX79 10mg/kg/Placebo+HLX01 and HLX79 20mg/kg/Placebo + HLX01 in Membranous Nephropathy and Lupus Nephritis (LN), sponsored by Shanghai Henlius Biotech. Recruiting at 17 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
39th of 50
24 · median 77
Started
2025
with 7 others
Phase 2
11 of 60
6 open now
Primary completion
2027-01
later than 17 of 36 live
Registered
46th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 39th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 17 of the 36 other live ones, and was the 46th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.

The secondary objective are to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HLX79 and HLX01, the clinical efficacy, the dynamic changes of biomarkers of HLX79 in combination with HLX01 in the treatment of glomerulonephritis.

The subjects will receive different doses of HLX79 (10, 20, or 30 mg/kg) or placebo, all in combination with HLX01. After the end of the first treatment period, subjects will enter a 20-week follow-up period and then undergo pre-second treatment period assessments. If the investigator determines that the subject does not require the second treatment period, the subject will continue in follow-up until completing the total 48-week follow-up period.

03

Conditions studied

  • Membranous Nephropathy
  • Lupus Nephritis (LN)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who voluntarily participate in this clinical study, fully understand and have been informed about the study, have signed the form (ICF), and are willing to follow and able to complete all study procedures.
  2. Male or female, aged 18-75 years (both inclusive) at the time of signing the ICF.
  3. Diagnosed with primary membranous nephropathy (MN) within 5 year prior to screening
  4. If a diagnosis of primary MN is confirmed, a renal pathological diagnosis prior to screening or a renal biopsy diagnosis obtained during screening should be available, or patients with nephrotic syndrome and a positive anti-PLA2R antibody test within 6 months prior to screening; secondary MN (secondary to infection, tumor, SLE, drugs, etc.) should be excluded; subjects should have received treatment with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blocker (ARBs) at the highest tolerated dose judged by the investigator for 3 months prior to screening (unless intolerance to ACEI/ARB, to their use or a low blood pressure that could induce side effects, at the investigator's discretion) and also meet one of the following high-risk criteria:

    • Urine protein > 8 g/24 h at screening.(The above 3-month ACEI/ARB treatment observation period is not required)
    • ≥ 60 mL/min/1.73 m2 and urine protein > 3.5 g/24 h at screening
  5. Women of (WOCBP) must undergo a pregnancy test at screening and obtain a negative result.
  6. WOCBP or male subjects must agree to take effective measures starting from signing the ICF until 12 months after the last dose of the medicinal product (IMP).

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women, or those with a positive blood pregnancy test prior to randomization.
  2. or partners of male subjects who plan to become pregnant during the study.
  3. History of drug or alcohol abuse within 1 year prior to screening.
  4. or increased risk of malignancy prior to screening: suspected and/or diagnosed with any malignancy (except for basal cell carcinoma, squamous cell carcinoma of skin in situ, or cervical carcinoma in situ occurring within 5 years prior to screening with no evidence of recurrence after treatment).
  5. History of organ transplantation or stem cell or bone marrow transplantation prior to screening, or plan to undergo the above-mentioned transplantations during the study.
  6. Complicated with primary immunodeficiency diseases, type 1 diabetes mellitus, and type 2 diabetes mellitus (Type 2 diabetic patients with a renal report within one year prior to screening that excludes diabetic nephropathy are eligible to participate in this study) before screening.
  7. Presence of the following diseases that are significantly unstable or poorly controlled at screening: cardiovascular disorder, hematological disease, respiratory disorder, digestive system disorder, endocrine and metabolic system disease, nervous system disorder or psychiatric disorders, skin and subcutaneous tissue disorders, musculoskeletal system disorder, immune system disorders, or Grade 3 or greater medical abnormalities ( v5.0), and the investigator believes that the subject should be excluded due to the above diseases or abnormalities, or the investigator believes that the above diseases or abnormalities may interfere with the interpretation of the study results.
  8. End-stage renal disease requiring kidney transplantation or dialysis, or oliguria (urine volume \< 400 mL/24 h) at screening or prior to randomization.
  9. Acute, recurrent, or chronic infection (including but not limited to tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacterial infection) at screening,
  10. Infection requiring intravenous or intramuscular injection of anti-infective drugs within 2 months prior to randomization, or infection requiring hospitalization within 2 months prior to randomization.
  11. Lung CT or chest X-ray at screening suggesting tuberculosis infection or previous tuberculosis infection.
  12. Abnormalities in 12-lead at screening, such as (QTc) interval > 450 ms in males and corrected QT (QTc) interval > 470 ms in females (Fridericia's method).
  13. Abnormal results of the following laboratory tests at screening:

    1. \< 90 g/L, or count \< 100 × 109 L, or \< 1.5 × 109 L.
    2. Alkaline phosphatase (ALP) > 2 × (ULN), or total (TB) > 2 × ULN, or (ALT) > 2 × ULN, or aspartate aminotransferase (AST) > 2 × ULN, or blood amylase > 1.5 × ULN.
    3. Estimated (eGFR) \< 30 mL/min/1.73 m2.
    4. (INR) > 2.5 (not on anticoagulant therapy).
    5. Interferon gamma release assay positive.
    6. Serological test positive for (HIV) antibodies.
    7. Test results positive for treponema pallidum (syphilis).
    8. Positive for virus (HBV) surface antigen (HBsAg), or positive for HBV core antibody (HBcAb) and HBV deoxyribonucleic acid (HBV-DNA).
    9. virus (HCV) infection (HCV antibody positive with HCV-RNA > ULN).
  14. History of serious drug allergy before screening: history of allergy to two or more drugs, or history of allergy or serious side effects to HLX01, HLX79, or their , or history of anaphylaxis to intravascular injection of contrast agents, human or murine proteins, or monoclonal antibodies, or history of anaphylactic shock.
  15. History of or need for treatment with one of the following drugs prior to screening:

    • Treatment with , MMF (or other forms of mycophenolate) within 1 month prior to randomization
    • Treatment with calcineurin inhibitors (CNIs) such as tacrolimus and cyclosporine A or other agents within 3 months prior to randomization
    • Treatment with alkylating agents such as cyclophosphamide (CYC) and ifosfamide within 6 months prior to randomization
    • Subjects who still require treatment with glucocorticoids, MMF (or other forms of mycophenolate), or alkylating agents or other immunosuppressive agents during the study as judged by the investigator at screening.
  16. Have received treatment with abatacept, telitacicept, JAK inhibitors, thalidomide, lenalidomide, bortezomib, cladribine, belimumab, rituximab, or other targeted drugs (T lymphocytes, B lymphocytes, interleukin-1, interleukin-6, type I interferon, etc.) within 1 year prior to randomization.Subjects who have received B-cell depleting drugs (such as rituximab) within the past year are eligible to participate in this study if there is evidence that the number of CD19+ or CD20+ B cells have recovered to the lower limit of normal or above.
  17. Have received intravenous infusion of immunoglobulin or plasma exchange within 3 months prior to randomization.
  18. Have participated in a clinical study of other medicinal products prior to screening, with an interval between this study and the previous study being too short: within 1 month prior to the first administration of this study or within 5 half-lives of the previous investigational medicinal product (whichever is longer). Or plan to participate in clinical studies of other investigational medicinal products before completing all scheduled assessments in this clinical study.
  19. Have participated in surgical or device clinical studies within 3 months prior to screening or plan to participate in other surgical or device clinical studies during this clinical study.
  20. Have received any live or within 3 months prior to screening, or plan to receive any live or live attenuated vaccine during the study.
  21. Use of herbal medicines, traditional Chinese medicines, or local traditional remedies that have therapeutic effects for MN within 14 days prior to randomization.
  22. Unable to establish venous access due to poor tolerability or difficulty in finding veins, or unable or unwilling to undergo repeated venipuncture.
  23. Donated whole blood or blood components (more than 400 mL) or lost a large amount of blood (more than 400 mL) within 2 months prior to screening, or plan to donate whole blood or blood components during the study.
  24. The investigator has a clear reason to believe that participation in this study will damage the rights and interests of the subject.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group A1

    Drug: HLX79 10mg/kg/Placebo+HLX01

  • Experimental
    Group B1

    Drug: HLX79 20mg/kg/Placebo + HLX01

  • Experimental
    Group C1

    Drug: HLX79 30mg/kg/placebo+HLX01

Interventions

  • DrugHLX79 10mg/kg/Placebo+HLX01

    Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2

  • DrugHLX79 20mg/kg/Placebo + HLX01

    Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2

  • DrugHLX79 30mg/kg/placebo+HLX01

    Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    Including incidence, nature, and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0, and the incidence of serious adverse events (SAEs), adverse events of special interest (AESIs), abnormal laboratory tests, vital signs, physical examination, and 12-lead ECG

    Time frame: 24 weeks

Secondary outcomes

  1. Assessment of safety

    Safety: Proportion of subjects with at least one Grade 3 or greater infection-related AE in each dose group according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE, and higher grades mean a worse outcome.

    Time frame: 52 weeks

  2. Plasma concentrations and PK parameters of HLX79 and HLX01

    Peak concentration (Cmax, Cmax, ss)

    Time frame: 52 weeks

  3. Plasma concentrations and PK parameters of HLX79 and HLX01

    Time to peak (Tmax, Tmax, ss)

    Time frame: 52 weeks

  4. Plasma concentrations and PK parameters of HLX79 and HLX01

    Area under the concentration-time curve (AUC0-inf, AUC0-t, AUC0-tau, AUCss)

    Time frame: 52 weeks

  5. Plasma concentrations and PK parameters of HLX79 and HLX01

    Elimination half-life (t1/2, t1/2, ss)

    Time frame: 52 weeks

  6. Plasma concentrations and PK parameters of HLX79 and HLX01

    Clearance (CL, CLss)

    Time frame: 52 weeks

  7. Plasma concentrations and PK parameters of HLX79 and HLX01

    Volume of distribution (Vz, Vss)

    Time frame: 52 weeks

  8. Plasma concentrations and PK parameters of HLX79 and HLX01

    Accumulation ratio (Rac)

    Time frame: 52 weeks

  9. PD

    Proportion of subjects with peripheral blood CD19+ B lymphocyte count ≤ 5/μL at weeks 12, 24, 36, and 52 of treatment, and proportion of subjects with peripheral blood CD20+ B lymphocyte count ≤ 1/μL at weeks 12, 24, 36, and 52 of treatment

    Time frame: 52 weeks

  10. Immunogenicity evaluation

    Positive rates of anti-drug antibody (ADA) and neutralizing antibody (NAb, if applicable) for HLX79 and HLX01

    Time frame: 52 weeks

  11. Assessment of clinical efficacy

    Proportion of subjects achieving complete remission (CR) or partial remission (PR) at weeks 12, 24, 36, and 52 of treatment.

    Time frame: 52 weeks

  12. Assessment of clinical efficacy

    Proportion of subjects negative for anti-M-type phospholipase A2 receptor (PLA2R) antibodies at weeks 12, 24, 36, and 52 of treatment.

    Time frame: 52 weeks

  13. Assessment of clinical efficacy

    Changes in anti-PLA2R antibody level from baseline at weeks 12, 24, 36, and 52 of treatment.

    Time frame: 52 weeks

  14. Explore the biomarkers

    Peripheral blood B lymphocyte counts or B lymphocyte kinetics: including the depletion kinetics of B lymphocytes and their subsets (CD20+ B lymphocytes, CD19+ B lymphocytes, and memory B lymphocytes)

    Time frame: 52 weeks

  15. Explore the biomarkers

    Peripheral blood B lymphocyte counts or B lymphocyte kinetics: the recovery kinetics of B lymphocytes and their subsets (e.g., CD20+ B lymphocytes, CD19+ B lymphocytes, and memory B lymphocytes).

    Time frame: 52 weeks

  16. Explore the biomarkers

    Serum immunoglobulins (IgA, IgG, and IgM).

    Time frame: 52 weeks

  17. Explore the biomarkers

    Serum complements (C3 and C4).

    Time frame: 52 weeks

  18. Explore the biomarkers

    Urine CD163

    Time frame: 52 weeks

07

Study locations

1 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
Jun 26, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Jan 2027
CompletionEst.
May 2030
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038382
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Aug 5, 2025
Primary completion
Jan 2027 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 18, 2025

Study contacts

Qi Jin
Contact
qi_jin@henlius.com
+86-15955160489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion